Shenyang Xingqi Pharmaceutical

Shenyang Xingqi Pharmaceutical is a leading Chinese ophthalmic pharmaceutical company with a broad commercial portfolio and robust R&D pipeline. Its marketed products include cyclosporine eye drops and sodium hyaluronate eye drops. The company is advancing multiple new drugs through late-stage clinical trials—including three Phase 3 studies of low-dose atropine for myopia control in children—and has several innovative therapies in earlier stages targeting dry eye, glaucoma, presbyopia, bacterial infections, age-related macular degeneration and macular edema. Recent clinical results show no adverse effects in a Phase 1 trial of an investigational eye drop product.